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Abstract
There is an urgent need to find consensus on screening, diagnosing and treating all degrees of DYSGLYCEMIA that may 
occur during pregnancies in Brazil, considering that many cases of DYSGLYCEMIA in pregnant women are currently not 
diagnosed, leading to maternal and fetal complications. For this reason the Brazilian Diabetes Society (SBD) and the 
Brazilian Federation of Gynecology and Obstetrics Societies (FEBRASGO), got together to introduce this proposal. We 
present here a joint consensus regarding the standardization of clinical management for pregnant women with any 
degree of Dysglycemia, on the basis of current information, to improve medical assistance and to avoid related 
complications of Dysglycemia in pregnancy to the mother and the fetus. This consensus aims to standardize the 
diagnosis among general practitioners, endocrinologists and obstetricians allowing the dissemination of information 
in basic health units, public and private services, that are responsible for screening, diagnosing and treating 
disglycemic pregnant patients.
1. Introduction
The organization of the health professions into specialties
and subspecialties according to body organs and systems
is often more pragmatic than scientific. The human
organism is a single unit composed of a seemingly infinite
number of biologic processes so intertwined that abnor-
malities of almost any of its parts or processes have pro-
found effects on multiple other body areas, exemplified in
this document by the common and complex theme of
Dysglycemia in pregnancy.
The aim of this document is to provide health profes-
sionals, especially endocrinologists, obstetricians and
general practitioners a better understanding of the cur-
rent consensus on screening, diagnosing and treating all
degrees of Dysglycemia that may occur during pregnan-
cies in Brazil, considering that many cases are currently
not diagnosed and consequently not treated leading to
maternal and fetal poor outcomes.
This is a joint consensus of the Brazilian Diabetes Soci-
ety (SBD) and the Brazilian Federation of Gynecology and
Obstetrics Societies (FEBRASGO) regarding the stan-
dardization of clinical management for pregnant women
with any degree of Dysglycemia, on the basis of current
information, to improve medical assistance and to avoid
related complications of Dysglycemia in pregnancy to the
mother and the fetus.
2. Dysglycemias in pregnancy
Dysglycemia is currently the most prevalent metabolic
alteration found during pregnancy [1]. Its prevalence dur-
ing pregnancy can be found in up to 13% of pregnant
women. The occurrence of type 1 diabetes (T1D) in the
pregnant population is of 0.1 %/year, of type 2 diabetes
(T2D) is of 2 to 3 %/year and that of gestational diabetes
(GD) is about 12-13 %, depending on the diagnostic crite-
ria used and the studied population [2]. In Brazil, the
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prevalence of GD found by the Brazilian Study of Gesta-
tional Diabetes Working Group was of 7.6% [3-5].
It is very important to know the type of diabetes under-
lying the dysglycemic state, since it can have different
impact in the course of pregnancy and in fetal develop-
ment. Pre-gestational diabetes, both T1D or T2D, is more
severe, because its effects start soon, during fertilization
and ovule's implantation, affecting mostly the organogen-
esis, leading to a higher risk of precocious miscarriages,
severe congenital malformations and fetal growth restric-
tion, mainly in those cases that are not adequately con-
trolled [6]. Besides fetal complications, maternal poor
outcomes can also be relevant, especially in the presence
of previous complications such as retinopathy and neph-
ropathy [7].
GD is generally diagnosed in the second half of preg-
nancy and affects especially fetal growth [8]. Fetuses of
mothers with GD have a greater risk to present with mac-
rosomia and neonatal hypoglycemia. Also, obesity and
impairment in the psychomotor development can occur
later on during lifetime [9]. If diabetes is diagnosed before
this period of pregnancy, it is probably a pre-existing dia-
betes of any type, that was present before pregnancy and
was not diagnosed.
3. Recommendations for patients with pre-existing 
diabetes
3. 1. Preconception information for women with pre-
existing diabetes
From adolescence onwards, advise women about the
importance of avoiding unplanned pregnancy [6] (B).
Inform women and their families about how diabetes
affects pregnancy and how pregnancy affects diabetes
[10]. Information and advice should cover the following
points:
• The impact of poor glycemic control in the course of
pregnancy and in the risks for the mother and the
fetus.
• The role of diet, weight, and exercise (including
weight loss advice for women who have a body mass
index above 25 kg/m2).
• The increased risk of having a baby who is large for
gestational age (LGA), increasing the likelihood of
birth trauma, induction of labor, and cesarean sec-
tion.
• The importance of maternal glycemic control dur-
ing labor and birth and early feeding of the baby to
reduce the risk of neonatal hypoglycemia.
• The possibility of transient morbidity (such as hypo-
glycemia or respiratory distress syndrome) in the
baby during the neonatal period, which may require
admission to a neonatal unit.
• The need for folic acid supplementation (600 mcg to
5 mg a day) until 12th gestation week to reduce the
risk of having a baby with a neural tube defect.
• The risks of hypoglycemia and of hypoglycemia
unawareness during pregnancy and the effects of nau-
sea and vomiting during pregnancy on glycemic con-
trol.
The need for assessment of diabetic retinopathy and
nephropathy before, during and after pregnancy, and the
risk of its worseningOffer preconception care and advice
to women who are planning to become pregnant before
they discontinue contraception. Inform them that estab-
lishing a good glycemic control before conception and
continuing it throughout pregnancy reduces- but does
not eliminate - the risks of miscarriage, congenital mal-
formations, stillbirth, and neonatal death [6] (B).
Offer a structured continuous education program that
will provide a better understanding of diabetes in preg-
nancy in what concerns diet, carbohydrate counting, cor-
rect insulin dose adjustment and self monitoring of blood
glucose (SMBG), as soon as possible, to women that are
planning to become pregnant. Assess the presence of
nephropathy, neuropathy, retinopathy, cardiovascular
disease, hypertension, dyslipidemia, depression and thy-
roid dysfunctions in women with diabetes who are con-
templating pregnancy, and start its treatment as soon as
possible [11].
3.2. Glycemic control before and during pregnancy
Advise women with pre-existing diabetes who are plan-
ning to become pregnant to keep their HbA1c concentra-
tion as close as possible to the normal range, if this is
safely achievable, avoiding the occurrence of hypoglyce-
mia [12]. The recommended level of HbA1c is below 6.0%,
or up to 1% above the maximum value informed by the
clinical analyses laboratory where the tests are per-
formed. Preferably, HbA1c test should be performed using
a Diabetes Control and Complications Trial (DCCT) -
aligned assay [12] (B). Reassure women that any reduc-
tion in HbA1c towards the target of 6.0% is likely to reduce
the risk of congenital malformations that occur more fre-
quently when diabetes is not under control at the begin-
ning of pregnancy. Women whose HbA1c is above 10%
should be strongly advised to avoid pregnancy until they
reach a better metabolic control, due to the high risk of
fetal malformations and miscarriages [13]. Pregnancy
should be planned when diabetes is under control and
preferably with HbA1c values within the normal range.
HbA1c test should be performed, at the first antenatal
visit, and then monthly until target levels <6% are
achieved, and every 2-3 months thereafter. Self monitor-
ing of blood glucose (SMBG) is a key component of dia-
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betes therapy during pregnancy and should be included
in the management plan. Daily SMBG, both before and
after meals, at bedtime and occasionally between 2:00
A.M. to 4:00 A.M., will provide optimal results in preg-
nancy [14] (C). Fingerstick SMBG is better than alternate
site testing in pregnancy, since it may not identify rapid
changes in glucose concentrations characteristic of preg-
nant women with diabetes [14] (C).
Glycemic control during pregnancy is considered excel-
lent when glycemic levels before meals, at bedtime and
between 2:00 A.M. to 4:00 A.M are between 60 and 105
mg/dl (3.5 and 5.9 mmol/l), with a postprandial peak
(measured one hour after beginning the meal) between
100 and 140 mg/dl (5.5 and 7.8 mmol/l). Women who
present increased risk of hypoglycemia should have these
targets during fasting state higher than 100 mg/dl (5.5
mmol/l). Glucose level 1-h after beginning the meal is the
closest value to the highest postprandial peak measured
by continuous glucose monitoring [14] (C).
3.3. Medical Nutrition therapy
Pregnant women with diabetes should receive individual-
ized medical nutrition therapy to achieve treatment
goals. Daily energy intake should be based on BMI, physi-
cal activity level, fetal growth pattern and the need to pre-
vent excess maternal weight gain and post-partum weight
retention [15]. The total recommended caloric content
should be composed by:
- 40-45 % carbohydrates
- 15-20 % proteins (minimum 1.1 g/kg/day)
- 30-40 % fat
Diet must also be planned aiming to promote carbohy-
drate intake along the day, to achieve optimal glycemic
control and to avoid hypoglycemia, hyperglycemia and
ketonemia. In general it is necessary to divide the total
daily food intake in 6 light meals [16] (C). Women that
are on insulin treatment should receive special attention
regarding insulin doses adequacy, the exact time of its
administration and to the nutritional content of each
meal. Bedtime meal should not be omitted and it has to
have 25 g of complex carbohydrates, besides proteins or
lipids to avoid hypoglycemia during the night.
The adjustment of prandial insulin can be done by car-
bohydrate counting every time the patient eats.
Nonnutritive sweeteners such as aspartame, saccharin,
acesulfame- K and sucralose can be moderately used [16]
(C).
3.4. Vitamins and trace elements supplementation
The supplementation of folic acid (600 μg to 5 mg a day)
from preconceptional period until the closure of neural
tube (12 weeks' gestation) is recommended for all preg-
nant women, including those who are diabetic, to reduce
the risk of having a baby with a neural tube defect [17]
(A).
Supplementation with other vitamins and trace ele-
ments should be done when nutritional deficiencies of
these vitamins and trace elements are detected [15] (C).
3.5. Physical activity/exercise
The benefits of exercise for pregnant women include a
sense of wellbeing, decreased weight gain, reduction of
fetal adiposity, improved glucose control, and better tol-
erance of labor [18]. Physical activity reduces insulin
resistance, which improves blood glucose utilization and
consequently blood glucose control. This effect can avoid
or postpone the need of insulin use in women with GD.
Physical activity of low intensity should be encouraged
for women previously sedentary if they have no contrain-
dications to practice it. Those already practicing exercise
before pregnancy should maintain their physical activity
if no contraindication is present. Contraindications for
the practice of physical activity during pregnancy are:
? Pregnancy induced hypertension
? Premature membranes' rupture
? Symptoms of preterm labor
? Persistent uterine bleeding after the second trimes-
ter
? Intrauterine fetal growth restriction
? Nephrotic syndrome
? Preproliferative and proliferative retinopathy
? Hypoglycemia unawareness
? Advanced peripheral and dysautonomic neuropathy
When indicated, physical activities should be per-
formed on most days of the week for a period of at least
30 minutes. Women should choose an activity that does
not have a risk of falling down or cause an abdominal
trauma, such as walking. The minimal target of 30 min-
utes can be divided into three 10-minutes sessions prefer-
ably after meals. Exercises must be conducted in an
appropriate environment, without excessive heat, to
avoid the risk of dehydration. Capillary blood glucose
should be monitored before and after exercises. Physical
activities should not increase blood pressure, cause uter-
ine contractions and fetal growth restriction [19] (B).
3.6. Pharmacological management (insulins and safety of 
medications for diabetes and its complications before and 
during pregnancy)
Because insulin preparations tested to date have been
determined not to cross or minimally cross the placenta,
insulin has been the treatment of choice in most parts of
the world for patients with gestational Dysglycemia.
Patients are advised to discontinue all oral hypoglycemic
agents, preferably before pregnancy or as soon as preg-
nancy is diagnosed and substitute with insulin, because of
its tested safety and efficacy in glycemic control. Recent
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trials have shown the safety of metformin during preg-
nancy [20-22] (B) and of the use of glibenclamide in
patients with GDM after the second trimester [23] (B).
Glibenclamide crosses the placenta minimally; met-
formin crosses the placenta in significant amounts and
although no adverse effects have been described, it seems
prudent to obtain further data before glibenclamide and/
or metformin become commonly prescribed during preg-
nancy.
For optimal glycemic control during pregnancy in
women with pre-existing diabetes, intensified insulin reg-
imens with multiple doses of subcutaneous long and
short-acting insulins or continuous insulin infusion, usu-
ally give the best results. In women who were using insu-
lin before pregnancy, it is generally necessary to reduce
the dose in about 10 to 20% during the first trimester.
Between the 18th and the 24th gestation week this dose
must be increased. During the third trimester, the
increased production of hormones by the placenta with
antagonistic effects to insulin makes it necessary to
increase insulin dose again, generally requiring doses that
are the double or triple of those used before pregnancy.
For converting women with T2D to insulin therapy, an
initial total daily dose of 0.7-1.0 unit/kg actual body
weight is often effective, adjusted according to subse-
quent blood glucose concentrations. After delivery, insu-
lin requirements fall dramatically, and many times in the
following days, insulin doses must be adjusted to half of
those used at the end of pregnancy or return to pre-preg-
nancy doses. The rapid acting insulin analogs, such as
insulin aspart and lispro are safe during pregnancy, lead-
ing to better postprandial glycemic levels and causing less
hypoglycemia [24] (B). NPH human insulin is still the
first choice for basal insulin [24] (A). There are not con-
sistent data regarding the use of the long acting insulin
analogs, detemir and glargine in pregnancy, although
many isolated reports and data of some studies have
shown promising results with their use (C). Continuous
subcutaneous insulin infusion can be used when avail-
able. The ideal sites for insulin injections during preg-
nancy are the abdomen and hips [24] (C).
In conclusion, management of GD with medication,
both oral and insulin, has been changing in the last years,
but quite slowly. Metformin is a logical option for women
with GD. It improves insulin sensitivity, probably by acti-
vating AMP kinase, and is not associated with weight
gain or hypoglycemia, but randomized trials to assess the
efficacy and safety of its use for GD are lacking. Recently
a randomized trial was conducted in Australia and New
Zealand, aiming exactly to assess its efficacy and safety in
this condition. A group of 751 women with GD was ran-
domly assigned at 20 to 33 weeks of gestation to open
treatment with metformin (with supplemental insulin if
required) or insulin. The primary outcome was a com-
posite of neonatal hypoglycemia, respiratory distress,
need for phototherapy, birth trauma, 5-minute Apgar
score less than 7, or prematurity. The trial was designed
to rule out a 33 % increase (from 30 to 40%) in this com-
posite outcome in infants of women treated with met-
formin as compared with those treated with insulin.
Secondary outcomes included neonatal anthropometric
measurements, maternal glycemic control, maternal
hypertensive complications, postpartum glucose toler-
ance, and acceptability of treatment. Of the 363 women
assigned to metformin, 92.6% continued to receive met-
formin until delivery and 46.3 % received supplemental
insulin. The rate of the primary composite outcome was
similar in both groups; 32.0 % in the group assigned to
metformin and 32.2 % in the insulin group. More women
in the metformin group than in the insulin group stated
that they would choose to receive their assigned treat-
ment again (76.6 vs. 27.2 %). The rates of other secondary
outcomes did not differ significantly between the groups.
There were no serious adverse events associated with the
use of metformin. So, it was concluded that in women
with GD, metformin (alone or with supplemental insulin)
is not associated with increased perinatal complications
as compared with insulin. The women preferred met-
formin to insulin treatment [20].
The use of sulfonylureas in GD is also controversial,
and rarely done, because of concern about teratogenicity
and hypoglycemia. There is also little information about
the efficacy of these drugs in this group of women. So, a
large clinical trial studied 404 women with singleton
pregnancies and GD that required treatment. The women
were randomly assigned between 11 and 33 weeks of ges-
tation to receive glibenclamide or insulin according to an
intensified treatment protocol. The primary end point
was achievement of the desired level of glycemic control.
Secondary end points included maternal and neonatal
complications. The mean (+/-SD) pretreatment blood
glucose concentration as measured at home for one week
was not statistically different: 114+/-19 mg/dl (6.4+/-1.1
mmol/l) in the glibenclamide group and 116+/-22 mg/dl
(6.5+/-1.2 mmol/l) in the insulin group. The mean con-
centrations during treatment were also not statistically
different: 105+/-16 mg/dl (5.9+/-0.9 mmol/l) in the glib-
enclamide group and 105+/-18 mg/dl (5.9+/-1.0 mmol/l)
in the insulin group. Eight women in the glibenclamide
group (4 %) required insulin therapy. There were no sig-
nificant differences between the glibenclamide and insu-
lin groups in the percentage of infants who were large for
gestational age (12 and 13 %, respectively); who had mac-
rosomia, defined as a birth weight of 4000 g or more (7
and 4 %); who had lung complications (8 and 6 %); who
had hypoglycemia (9 and 6 %); who were admitted to a
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neonatal intensive care unit (6 and 7 %); or who had fetal
anomalies (2 and 2 %). The cord-serum insulin concen-
trations were similar in the two groups, and glibencl-
amide was not detected in the cord serum of any infant in
the glibenclamide group. It was concluded then that in
women with GD, glibenclamide is a clinically effective
alternative to insulin therapy [23].
The decision to begin insulin therapy may be a choice
for a gestational diabetic woman and her physician when
the medical nutrition therapy is too difficult to maintain
glycemic levels in acceptable ranges. Those with preges-
tational diabetes generally have to change their insulin
regimen. Depending on the type, severity, and stage of
diabetes, patients may have only elevated postprandial
glucose levels and normal fasting blood glucose levels, or
the fasting glucose levels may be elevated as well. If post-
prandial glucose is the target of treatment, the rapid-act-
ing insulin analogs lispro and aspart, appear to be as safe
and effective as regular human insulin, achieving better
postprandial glucose concentrations with less late pran-
dial hypoglycemia. If the patient has elevated fasting and
postprandial blood glucose levels and requires multiple
daily injections to achieve good glycemic control, a basal-
bolus regimen should be considered. The long-acting
insulin analogs do not have as pronounced a peak effect
as NPH insulin and therefore cause less nocturnal hypo-
glycemia. However, the safety of these insulin analogs
needs to be further established in pregnant women.
Issues that will need to be further clarified include the
question of whether these insulin analogs have terato-
genic effects on the developing fetus, alter the balance
between the binding affinity to IGF-I receptor and insulin
receptor, are associated with increased risk of retinopa-
thy, or show increased antibodies levels. Because the lack
of information, large-scale controlled clinical trials are
warranted [24].
Discontinue angiotensin converting enzyme inhibitors
and angiotensin II receptor antagonists, due to its associ-
ation with embriopathies and fetopathies, before preg-
nancy or as soon as pregnancy is confirmed, and
substitute them with alternative anti-hypertensive agents
suitable for use during pregnancy [25,26] (A). These
agents are: methyldopa, long acting nondihydropyridine
calcium channel blockers and beta blockers with partial
beta agonist activity like carvedilol, labetalol and pin-
dolol; the use of atenolol has been associated with fetal
growth restriction and must be avoided [27] (C).
Discontinue statins before pregnancy or as soon as
pregnancy is confirmed, due to its potential teratogenic
effects [28,29] (A).
It is still not clear if the use of fibrates in pregnancy is
safe or not; it should be used only in cases of severe
hypertrygliceridemia, when no response to diet is met
and if there is an increased risk of developing acute pan-
creatitis [27] (D).
3.7. Management of diabetic emergencies and 
complications during pregnancy
Advise and teach women with insulin treated diabetes
about the risks of hypoglycemia and how to prevent it,
particularly during the night and during the sleeping
hours. Advise women, their partners and other family
members about these risks and empower them to give the
first aid without delay [24] (B).
Exclude diabetic ketoacidosis as a matter of urgency in
women with T1D who present with any infectious dis-
ease, dehydration and high glycemic levels [10] (D).
Offer retinal and renal assessment to women with pre-
existing diabetes before, during and after pregnancy
because diabetic retinopathy may worsen during preg-
nancy and diabetic nephropathy is associated with
adverse pregnancy outcomes such as intrauterine growth
restriction, preeclampsia and preterm birth. The risk of
worsening a proliferative retinopathy is extremely high in
those women that did not receive previous laser therapy.
Ischemic coronary disease, if not treated is associated to
high mortality rates [10] (B).
4. Recommendations for patients with gestational 
diabetes
Gestational diabetes (GD) is defined as carbohydrate
intolerance of varying degrees of severity with onset or
first recognition during pregnancy, regardless of whether
insulin is used for treatment or the condition persists
after pregnancy. It does not exclude the possibility that
unrecognized glucose intolerance may have antedated the
pregnancy [30]. The importance of diagnosing diabetes
during pregnancy was reinforced by the fact that a greater
frequency of miscarriages, macrosomia and perinatal
mortality was found in the offspring of women that devel-
oped diabetes during pregnancy, when compared to the
control group [30]. It generally represents the early onset
of T2D that occurs during pregnancy and has many risk
factors such as:
- Advanced ages (generally = 35 years)
- Overweight, obesity (BMI = 25) before pregnancy or
in the first trimester and/or excessive weight gain in
the index pregnancy [31,32]
- Family history of diabetes in first degree relatives
- Excessive fetal growth (macrosomia or large for ges-
tational age [LGA] fetuses), polyhydramnio, hyper-
tension or preeclampsia in the index pregnancy
- Poor obstetric history: previous miscarriages, con-
genital malformations, fetal or neonatal death, mac-
rosomia or gestational diabetes
- Polycystic ovaries syndrome
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- Use of drugs that can cause hyperglycemia, like thi-
azidic diuretics, corticosteroids, excessive doses of
thyroid hormones etc...
There is great controversy about the indication of
screening for GD in the literature. The majority of recom-
mendations come from consensus done by groups of spe-
cialists [10] (D). In the present moment, current
recommendations are evidence-based; the screening for
GD must be universal, what means that all pregnant
women must be investigated. All women should have
their plasma glucose level measured at the first antenatal
visit. If fasting glycemia is = 85 mg/dl (4.7 mmol/l), an
oral glucose tolerance test should be performed immedi-
ately in order to detect a pre-existing, non diagnosed dia-
Figure 1 Algorithm for the diagnosis of gestational diabetes. * Confirmed with a 2nd abnormal value.
PREGNANT WOMAN
without risk factors for GD
< 85 mg/dl 85-125 mg/dl 126 mg/dl *
75g OGTT
between
24-28th wk
DIABETES75g OGTT 
immediately
 
NORMAL IMPAIRED
GLUCOSE 
TOLERANCE
NORMAL IMPAIRED
GLUCOSE 
TOLERANCE
DIABETES
Repeat OGTT
between 24-28 wk-
END 
INVESTIGATION DIABETES
PREGNANT WOMAN
with risk factors for GD
<126 mg/dl 126 mg/dl *
DIABETES75g OGTT
NORMAL IMPAIRED
GLUCOSE 
TOLERANCE
  
immediately
DIABETES
Repeat OGTT
between 24-28 wk-
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betes. If the test is normal, it should be repeated between
the 24th-28th gestation weeks (Figure 1).
For the diagnosis of GD, the three hour 75 g oral glu-
cose tolerance test (OGTT) must be performed between
the 24th - 28th gestation weeks. The American Diabetes
Association's diagnostic criteria for GD, use the cutoff
points suggested by Carpenter & Coustan, with blood
glucose levels = 95 mg/dl (5.2 mmol/l, = 180 mg/dl (10.0
mmol/l) and = 155 mg/dl (8.6 mmol/l), at fasting, 1 and 2
hrs, respectively; two or more altered points lead to the
diagnosis of GD (Table 1) [4,33]. Recently, in a workshop
for experts that took place in Pasadena, California in June
2008, sponsored by the International Association of Dia-
betes and Pregnancy Study Groups (IADPSG), it was
decided that the GD diagnosis criteria should be based on
the findings of the HAPO study, an observational trial
that aimed to clarify the accurate glucose threshold that
links maternal hyperglycemia and adverse perinatal out-
comes [34]. It was then suggested new cutoff points for
fasting, 1 and 2 hrs of blood glucose = 92 mg/dl (5.1
mmol/l), ≥180 mg/dl (10.0 mmol/l) and ≥153 mg/dl (8.5
mmol/l), respectively. It was then, discussed the possibil-
ity that only one value above the normal could lead to the
diagnosis of GD (ADA 2009, not published). These crite-
ria were recently approved by the International Diabetes
Federation (IDF 2009, not published) (Figure 1).
It is of importance to notice that these tests must be
performed three days after the consumption of a diet
containing more than 150 g of carbohydrates daily; the
patient cannot smoke during the test and must stay
seated or laid down.
Fasting glycemia of 100 mg/dl (5.5 mmol/l), considered
the upper level for normal adults is not valid in preg-
nancy. Diagnosis of GD should not be done with random
blood glucose (except when the levels of glycemia are
≥200 mg/dl [11.1 mmol/l]), with 50 g glucose challenge
test or urine analyses for glucose [10] (B).
Inform women with GD about the effects of GD on
pregnancy; tell them that good glycemic control through-
out pregnancy will reduce the risks of fetal macrosomia,
trauma during birth (to themselves and the baby), induc-
tion of labor or cesarean section, neonatal hypoglycemia,
and perinatal death. Instruct them on self monitoring
blood glucose. Targets for blood glucose control are the
same as for women with pre-existing diabetes.
Recent studies have evidenced that intervention in
women with GD can prevent the occurrence of many
adverse outcomes [35] (B), even in those women present-
ing with less severe degrees of Dysglycemia, that are not
considered as diagnostic of GD [31,32] (A). The initial
approach to GD consists in tailoring a diet that will allow
adequate weight gain and normalization of glycemia. The
total caloric amount of the diet should lead to a weight
gain of about 300-400 g per week after the second trimes-
ter of pregnancy [15].
Regular physical activities are part of the treatment of
GD, taking always in account the presence of any kind of
obstetric contraindication [18] (B).
Pharmacological therapy must be considered if diet and
exercise fail to maintain blood glucose targets during a
period of one to two weeks (fasting = 95 mg/dl [5.2
mmol/l] and 1 hr postprandial ≥140 mg/dl [7.8 mmol/l])
[36] (B). Glycemic control should be done with one fast-
ing and two postprandial glycemias performed daily or at
least weekly, when there exists no conditions for self
monitoring of blood glucose. Excessive fetal growth,
observed in an ultrasound investigation done between
the 29th and 33rd gestation weeks, that shows a fetal
abdominal circumference above the 70th centile can be
used to consider pharmacological therapy [37] (B). The
standard hypoglycemic therapy approach is the addition
of exogenous insulin. Starting doses average 0.6-1.0 units/
kg depending on the stage of gestation. Combinations of
intermediate or long acting preparations with short or
rapid-acting preparations are useful to reach glucose tar-
gets and improve fetal outcomes. Insulin frequently is
stopped after delivery. It is necessary reassess maternal
glucose levels post partum to evaluate if the patient per-
sisted dysglycemic, and if so, it is necessary to identify the
type of diabetes that is present.
Table 1: Diagnosis of gestational diabetes using 75 g Oral Glucose Tolerance Test.
ADA, SBD, and
FEBRASGO*
International Association of Diabetes 
and Pregnancy Study Groups (IADPSG)
(ADA and IDF meetings 2009
-unpublished data)**
Fasting ≥95 mg/dl (5.27 mmol/l) ≥92 mg/dl (5.11 mmol/l)
1 hr ≥180 mg/dl (10.0 mmol/l) ≥180 mg/dl (10.0 mmol/l)
2 hrs ≥155 mg/dl (8.61) mmol/l) ≥153 mg/dl (8.5) mmol/l)
* Two altered values are considered diagnostic of GDM
** One altered value is considered diagnostic of GDM
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5. Antenatal care appointments
Offer pregnant women with diabetes, either pre-existing
or GD an education program provided by a diabetes care
team.
Antenatal appointments should cover care specifically
for women with diabetes in addition to the care that is
provided routinely for healthy pregnant women.
Assessment of glycemic control should be performed
every one to two weeks by the physician and/or other
members of the diabetes care team.
Prioritize women with pregestational diabetes to per-
form a fetal echocardiography for evaluation of the four
chamber of fetal heart, aiming to visualize any kind of
anatomic or functional dysfunction [25] (A).
The aims of fetal evaluation are to observe vitality in
the first trimester, structural integrity in the second tri-
mester and monitor fetal growth and wellbeing in the
third trimester (Table 2).
Those women who present with poor glycemic control
and/or with hypertension, should have anticipated and
performed in shorter periods of time those tests that
evaluate fetal wellbeing, since the risk of fetal death is
proportional to the degree of maternal hyperglycemia
and hypertension.
6. Preterm labor in women with diabetes
Antenatal steroids for fetal lung maturation are not con-
traindicated but should be administered with additional
insulin in women with insulin treated diabetes [10] (D).
Tocolysis for inhibition of preterm labor is not con-
traindicated, but do not use betamimetics for tocolysis in
women with diabetes [10] (D).
7. Timing and mode of birth
Diabetes is not an absolute indication for cesarean sec-
tion. In women with diabetes with a good metabolic con-
trol the mode of birth should be vaginal.
An anesthetic assessment can be offered to relieve
labor's pain, especially in women with co-morbidities
such as obesity and autonomic neuropathy.
Capillary blood glucose levels should be monitored
every hour during labor and birth and in the post anes-
thetic period.
Offer elective, through induction of labor or, if indi-
cated, elective cesarean section, when there is maternal
or fetal indication [10] (D).
8. Glycemic control during labor and birth
Capillary blood glucose should be monitored hourly dur-
ing labor and birth to maintain glucose levels between 70
and 140 mg/dl (3.88 and 7.8 mmol/l); if the concentration
is not maintained in this range, use continuous intrave-
nous dextrose and insulin infusion [10] (D).
In women with DM1, consider intravenous dextrose
and insulin infusion from the onset of labor [10] (D).
Women that use insulin pumps for continuous insulin
infusion must change their basal/bolus ratios, depending
on the type of labor.
9. Initial assessment and care of the newborn baby
Advise women to give birth in hospitals where advanced
neonatal resuscitation skills are available 24 hours a day;
keep babies with their mothers unless a clinical complica-
tion or abnormal clinical signs arise that warrant admis-
sion for an intensive or special care unit [10] (A).
Feed babies as soon as possible after birth (within 30
minutes) and then every two to three hours until feeding
maintains prefeed blood glucose concentrations of at
least 40 mg/dl (2.22 mmol/l). Test blood glucose concen-
trations at two to four hours after birth. Only if concen-
trations are below 40 mg/dl (2.22 mmol/l) in two
consecutive readings despite maximal support for feed-
ing, or if there are abnormal clinical signs, or if the baby
will not feed orally effectively, should additional measures
such as tube feeding or intravenous dextrose be given.
Test blood glucose in babies who present with clinical
Table 2: Recommendations for fetal evaluation in 
pregnancy complicated by diabetes.
1st Trim. US to evaluate gestational age/nuchal 
transparency thickness and screen fetal 
malformations
2nd Trim. Morphologic US to screen malformations 
- 20-24th gestation week
Uterine and umbilical arteries doppler - 
20th gestation week
Fetal Echocardiogram - 24-26th gestation 
week (in preexisting diabetes)
US monthly 24th gestation week 
onwards to evaluate fetal growth and 
polyhydramnio
3rd Trim. Monthly US until delivery. In case of fetal 
growth restriction or LGA, it should be 
performed every two weeks
Basal CTG between 24-28th gestational 
week in cases of preexisting diabetes
Umbilical arteries doppler in the 
presence of hypertension, preeclampsia 
or vasculopathy. Monthly US from 24th 
gestational week to evaluate fetal 
growth and the presence of 
polyhydramnios
Daily Fetal movements count - 3×/day 
after 28th gestation weeks with patient on 
left side decubitus
* US = Ultrasound ** LGA = Large for gestational age *** CTG = 
Cardiotocography
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signs of hypoglycemia (such as abnormal muscle tone or
low level of consciousness, fits, apnea) and start treat-
ment with intravenous dextrose as soon as possible [10]
(A).
Perform echocardiography for babies who show clinical
signs associated with congenital heart disease (including
heart murmur) or cardiomyopathy.
Do not test for polycythemia, hyperbilirubinemia,
hypocalcaemia, or hypomagnesaemia unless the baby has
clinical signs.
Recognize criteria for admission to a neonatal unit,
such as hypoglycemia associated with abnormal clinical
signs, respiratory distress, signs of cardiac decompensa-
tion, or neonatal encephalopathy.
10. Postnatal management of diabetes
8.1. Pre-existing diabetes
• Breastfeeding should be encouraged. Exclusive breast-
feeding is the ideal nutrition, and provides protection
against infections in infants [38] (A).
• Reduce insulin immediately after the birth in women
with insulin treated pre-existing diabetes. Monitor blood
glucose levels carefully to establish the appropriate dose,
and inform women of the increased risk of hypoglycemia
in the postnatal period, especially if breastfeeding (It is
advisable to eat a meal or snack before or during feeds)
[15] (D).
Resume (or continue) use of metformin and glibencl-
amide immediately after birth in women with pre-exist-
ing T2D diabetes who are breastfeeding. Only 0.4% of
metformin dose taken by the mother is detected in
maternal milk, and this is not dependent on the time the
drug was taken.
• Studies done with small number of cases (maximum 9
children), did not detect the drug in the babies [39-41].
Glibenclamide and glipizide were not detected in mater-
nal milk and no hypoglycemia was reported in the babies,
although the number of studied cases was small [42].
(Table 3).
• Refer women with pre-existing diabetes back to their
routine diabetes care arrangements; remind them of the
importance of contraception and the need for preconcep-
tion care when planning future pregnancies.
8.2. Gestational diabetes
• Discontinue insulin therapy immediately after the birth
in women who were diagnosed with GD; test their blood
glucose to exclude persisting hyperglycemia before trans-
fer to community care, and remind them of the symp-
toms of hyperglycemia.
• Offer lifestyle advice (on weight control, diet, and
exercise) and an OGTT performed with 75 g glucose load
six weeks after delivery, adopting WHO's criteria for dia-
betes out of pregnancy, that is a fasting glycemia = 126
mg/dl (7.0 mmol/l) and/or glycemia = 200 mg/dl (11.1
mmol/l) two hours after the glucose load. Patients who
present a fasting glycemia between 100 mg/dl (5.5 mmol/
l) and 125 mg/dl (6.94 mmol/l) are classified as having an
impaired fasting glucose (IFG), and those who present a
glycemia between 140 mg/dl (7.8 mmol/l) and 199 mg/dl
(11.06 mmol/l) two hours after glucose load, are consid-
ered as having an impaired glucose tolerance (IGT). If the
test is normal consider performing at least a fasting
Table 3: Use of anti-diabetic medications in women with diabetes during lactation.
Drug Milk transfer Permission to use during 
lactation
Reference
Glibenclamide No Yes [42]
Glicazide Unknown No Not published
Glipizide No Yes [42]
Glimepiride Unknown No Not published
Metformin Less than1% Yes [39-41]
Acarbose Less than 2% No http://www.fda.gov
Rosi and pioglitazone Rosi detected in milk from 
lactating rats.
Pio not published
No http://www.fda.gov
Sita and vildagliptine Sitagliptin is secreted in the 
milk of lactating rats at a milk 
to plasma ratio of 4:1. It is not 
known whether sitagliptin is 
excreted in human milk. Vilda 
not published
No http://www.fda.gov
Exenatide Unknown No Not published
Negrato et al. Diabetology & Metabolic Syndrome 2010, 2:27
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Table 4: Safety for use of common prescribed drugs for women with diabetes during pregnancy and breastfeeding.
Drug Safety for
use during pregnancy
Safety for
use during lactation
Level of
evidence
SWEETENERS
aspartame, saccharin, 
acesulfame-K and sucralose
Moderately moderately C
ORAL ANTIHYPERGLICEMIC 
AGENTS
Glibenclamide No consensus Yes B
Glicazide No No B
Glipizide No Yes B
Glimepiride No No B
Metformin No consensus Yes B
Acarbose No No C
Rosi and pioglitazone No No C
Sita and vildagliptin No No C
Exenatide No No D
INSULIN
NPH Yes Yes A
Regular Yes Yes A
Lispro Yes Yes B
Aspart Yes Yes B
Gargine No consensus No consensus C
Detemir No consensus No consensus C
ORAL ANTIHYPERLIPIDEMIC 
AGENTS
Gemfibrozil No No A
Statins No No A
ANTIHYPERTENSIVE
Enalapril No With caution A
Captopril No No A
Lisinopril No No A
Methyldopa Yes Yes A
Losartan No With caution A
Candesartan No No A
Hydrochlorothiazide (low 
doses)
Yes Yes C
Calcium channel Inhibitors No Yes C
Beta- blockers(labetalol, 
metoprolol, propanolol)
Yes Yes B
Atenolol No No A
THYROID HORMONES
Levothyroxine Yes Yes A
ANTITHYROID DRUGS
Methimazole With caution Yes B
Propiltiouracil Yes Yes B
Iodine No No A
Negrato et al. Diabetology & Metabolic Syndrome 2010, 2:27
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plasma glucose measurement annually thereafter (B).
Levels of HbA1c higher than 6.5% should be considered as
diagnostic of diabetes [43]. Provide information about the
risk of GD in future pregnancies, offer screening for dia-
betes when planning future pregnancies, and indicate
early OGTT in future pregnancies and also self monitor-
ing blood glucose.
8.3. Treatment of co-morbidities after delivery
• Lipid Therapy: Statins and fibrates should not be used
during breastfeeding because they pass through breast
milk and due to the potential for adverse effects to the
infant (manufacturers' reports). When triglycerides levels
are above 1000 mg/dl (55.55 mmol/l) in the presence of
an appropriate diet, due to the high risk of pancreatitis,
niacin, fish oil (free of mercury) or quitting breastfeeding
should be considered.
• Antihypertensive Therapy: Use of ACE inhibitors, cal-
cium channel blockers, low dose thiazides and Methyl-
dopa during breastfeeding, even being transferred to the
milk in small amounts, are safe [27]. Atenolol has been
associated with bradycardia and hypotension in infants
[44]. Propranolol and metoprolol could be indicated but
infants should be monitored for manifestations of beta-
blockade (C).
11. Contraception
Contraceptive counseling is an effective method for
avoiding the undesirable consequences of an unplanned
diabetic pregnancy. No one contraceptive method is
appropriate for all women with diabetes, and counseling
must be individualized.
If an oral contraceptive is the best choice, a low-dose
combined (estrogen+ progestin) or sequential pill with
≤35 μg estrogen and a new progestin (levonorgestrel, des-
ogestrel, gestodene, or norgestimate) low dose may be
better, but the risk of cardiovascular effects must be con-
sidered. Progestin-only pills offer an alternative, but there
is the possibility of elevated blood lipid levels and other
effects.
Use of long acting injectable progestin is no longer rec-
ommended for diabetic patients.
Cooper-containing intrauterine devices appear to
expose diabetic women to greater risk of infection when
compared to non diabetic women.
Barrier methods such as diaphragm plus spermicide or
condom plus foam, present high failure rate.
Rhythm increases failure rate, since diabetic women
may not have regular menstrual cycles.
Once childbearing is completed, permanent steriliza-
tion of the diabetic woman or her mate may offer an
acceptable means to prevent unplanned pregnancy com-
pared with other contraceptive methods [45].
12. Final considerations
Drugs that can be used by pregnant diabetic women dur-
ing pregnancy and breastfeeding can be seen in Table 4.
The most important items highlighted in this consensus
can be seen in Table 5, with the evidence levels of the
main recommendations and conclusions.
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Table 4: Safety for use of common prescribed drugs for women with diabetes during pregnancy and breastfeeding. (Continued)
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Table 5: Evidence levels of the main recommendations and 
conclusions.
Recommendations and Conclusions Evidence
Level
• Diabetic patients must start pregnancy in ideal 
metabolic conditions (HbA1c < 6% or 1% above 
the maximum value used by the clinical 
analyses laboratory).
B
• Advise patients to self monitor capillary blood 
glucose before and after meals, at bedtime and 
sporadically between 2:00 and 4:00 AM.
C
• The amount of calories prescribed must be 
based on BMI. The total caloric amount 
recommended must be composed by: 40 to 
45% carbohydrates, 15-20% proteins (minimum 
of 1, 1 mg/kg/day) and 30-40% fat.
B
• Use of folic acid before pregnancy until neural 
tube closure is recommended for all women 
including those with diabetes.
A
• Regular practice of physical activity will cause 
a wellbeing sensation, less weight gain, 
reduction in fetal adiposity, a better glycemic 
control and fewer problems during labor. 
Physical activity is contraindicated in case of: 
Pregnancy induced hypertension, premature 
membranes' rupture, preterm labor, persistent 
uterine bleeding after the second trimester, 
intrauterine growth restriction, nephrotic 
syndrome, pre and proliferative retinopathy, 
hypoglycemia unawareness, advanced 
peripheral neuropathy and dysautonomia
A
• In most parts of the world the 
recommendation is to discontinue the use of 
antidiabetic oral agents and its substitution for 
insulin, before pregnancy or soon after its 
diagnosis. Recent trials have shown the safety 
of metformin during pregnancy and the use of 
glibenclamide in patients with GD after the 
second trimester.
B
• Rapid acting insulin analogs such as insulin 
aspart and lispro are safe during gestation, lead 
to a better control of postprandial levels of 
glycemia and lower frequency of 
hypoglycemia. NPH human insulin is still the 
first choice among those intermediate acting 
insulins. There are some studies and short 
communications with the use of long acting 
insulin analogs detemir and glargine, but more 
consistent studies are warranted.
A
• Discontinue the use of angiotensin converting 
enzyme inhibitors, of angiotensin II receptor 
agonists and statins before pregnancy or as 
soon as it is confirmed, due to its association 
with embriopathies and fetopathies
A
• In order to simplify the diagnosis of GD, a 
fasting glycemia must be performed in the first 
antenatal visit. If glycemic level is ≥85 mg/dl 
and the patient shows risk factors for GD, a 75 g 
OGTT must be performed. If the test is normal, it 
must then be repeated between 24th and 28th 
gestation weeks.
A
• Diagnosis of GD should not be done with a 
random glycemia, with a 50 g glucose challenge 
test and urine glucose testing.
Between 24-28th gestation weeks, a fetal 
echocardiography should be performed to 
evaluate the four fetal heart chambers, aiming 
to diagnose any kind of anatomic or functional 
dysfunction.
B
• Perform an OGTT six weeks after delivery, and 
then, at least a fasting glycemia annually.
B
Table 5: Evidence levels of the main recommendations and 
conclusions. (Continued)
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